Recently, the FDA announced a major update that has left many patients wondering about the future of their weight loss treatments. Mounjaro (tirzepatide) and Zepbound, two highly effective medications for weight loss and diabetes management, are no longer in shortage. While this is good news, it also means that compounded tirzepatide—a custom-made version of the drug that filled the gap during the shortage—will no longer be available.
This sudden change may feel like a disruption, but at QuickMD, we’re here to make the transition easier. Whether you’re currently using compounded tirzepatide or exploring brand-name alternatives like Mounjaro, we’ve got affordable, convenient solutions to help you stay on track.
What Exactly Changed with the FDA’s Announcement?
Before diving into the details, it’s helpful to understand the FDA’s role in all of this.
Understanding the FDA’s Role
The Food and Drug Administration (FDA) oversees the safety and availability of medications in the U.S. They determine whether a drug is safe, effective, and available for widespread use.
When a medication is in short supply, the FDA can allow pharmacies to create compounded versions—custom-made alternatives—to help bridge the gap.
The Mounjaro Shortage: Why It Happened
Mounjaro (tirzepatide) is a prescription medication that has been making waves in both diabetes management and weight loss treatments. Its effectiveness has led to skyrocketing demand, which in turn led to a shortage.
To ensure patients didn’t go without their medication, pharmacies were allowed to create compounded tirzepatide—a custom version of the same active ingredient.
The New FDA Update: No More Shortage
In October 2024, the FDA announced that the shortage of Mounjaro and Zepbound was officially over. While this is great news for patients who prefer brand-name medications, it also means that compounded tirzepatide is no longer allowed to be produced or prescribed.
So, if you’ve been relying on compounded tirzepatide, this might feel like a big change. But don’t panic—affordable and effective options are still available to you, and QuickMD is here to help guide you through this transition.
Why This Change Matters for You
If you’ve been using compounded tirzepatide, you may be worried about what this shift means for your treatment and budget.
At QuickMD, we understand these concerns, and we’re here to make sure you have the support you need during this transition. We’re offering affordable pricing for brand-name Mounjaro so you can continue your treatment with peace of mind.
Our Solution: Affordable Mounjaro Pricing
We know switching from compounded medications to brand-name drugs can often mean higher costs. That’s why we’ve worked hard to keep our prices low and competitive.
Here’s what we’re offering:
| Dosage | Monthly Price |
| Up to 5mg weekly | $399 |
| 7.5mg to 12.5mg weekly | $699 |
| 15mg weekly | $829 |
These prices are hundreds of dollars less than most other providers, making it easier for you to transition from compounded tirzepatide to Mounjaro without breaking the bank.
What Should You Do Next?
If you were previously using compounded tirzepatide, don’t worry. QuickMD has made the transition to brand-name Mounjaro simple, affordable, and fast.
Here’s what you can do:
- Book a quick online consultation with a QuickMD provider. You’ll receive expert advice on whether Mounjaro is suitable for you or if you should consider other options, like compounded semaglutide.
- Receive your prescription for Mounjaro, and enjoy the convenience of having it shipped directly to your door—no pharmacy visits, no waiting in line.
- Stay informed: We’re working closely with suppliers to ensure our pricing remains affordable, and we’ll keep you updated on any future developments regarding medications and availability.
Ready to get started? Learn more about your treatment options and get your Mounjaro prescription today.
FAQs
Why is compounded tirzepatide no longer available?
Compounded tirzepatide was created as an alternative during the Mounjaro shortage. Now that the FDA has confirmed that the supply of Mounjaro and Zepbound has stabilized, compounded versions are no longer allowed to be sold. Brand-name Mounjaro is once again widely available.
What’s the difference between Mounjaro and compounded tirzepatide?
Mounjaro is the FDA-approved brand name for tirzepatide. It ensures you’re receiving a consistent, well-regulated product. Compounded tirzepatide was a workaround during the shortage but is not FDA-approved in the same way. It was meant to temporarily fill the gap.
What if I can’t afford brand name Mounjaro?
QuickMD is committed to providing affordable options. With prices starting at $399 per month, we offer some of the lowest rates available for brand name Mounjaro. We also offer consultations for compounded semaglutide, a lower-cost alternative available through our services.
Compounded Semaglutide: A Viable Alternative
If you’re concerned about the cost of Mounjaro or want to explore other options, our providers can also discuss compounded semaglutide with you. Semaglutide, the active ingredient in Ozempic and Wegovy, is another highly effective medication for weight loss and diabetes management.
At QuickMD, we’re happy to discuss whether compounded semaglutide might be a better fit for your needs during your next consultation.
QuickMD Is Here to Help
Navigating changes in the healthcare system—especially regarding FDA regulations and medications—can feel overwhelming. But you’re not alone. QuickMD is dedicated to making this transition as smooth as possible. With affordable Mounjaro pricing, continued access to compounded semaglutide, and expert support, we’re here to ensure your treatment remains both effective and budget-friendly.
We’ve been helping patients manage their weight and health since 2022, and we’re proud to offer a wide range of solutions tailored to your unique needs.
Ready to make the switch to brand-name Mounjaro? Learn more about your options and get started today!
